Posted by Michael Wonder on 01 Aug 2022
Marinus Pharmaceuticals announces U.S. commercial launch of Ztalmy (ganaxolone) for seizures associated with CDKL5 deficiency disorder
1 August 2022 - ZTALMY One™ offers comprehensive patient services, including access and prescription drug support.
Marinus Pharmaceuticals today announced the U.S. commercial launch of ZTALMY® (ganaxolone) oral suspension, CV for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.
